{"id":56024,"date":"2021-02-04T13:03:03","date_gmt":"2021-02-04T12:03:03","guid":{"rendered":"http:\/\/www.veeva.com\/eu\/?post_type=resources&p=56024"},"modified":"2025-10-21T12:04:29","modified_gmt":"2025-10-21T10:04:29","slug":"6-of-the-top-7-global-cros-partner-with-veeva-to-run-faster-clinical-trials-for-sponsors","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/6-of-the-top-7-global-cros-partner-with-veeva-to-run-faster-clinical-trials-for-sponsors\/","title":{"rendered":"6 of the Top 7 Global CROs Partner with Veeva to Run Faster Clinical Trials for Sponsors"},"content":{"rendered":"

Leading CROs now accelerating study builds and launching higher quality clinical trials<\/em><\/p>\n

BARCELONA, Spain \u2014 4 Feb., 2021 \u2014<\/strong>Veeva Systems<\/a> (NYSE: VEEV) today announced that 6 out of the top 7 global CROs have joined the Veeva Vault CDMS<\/a> partner program. Accelerating clinical research is a top priority in the life sciences industry. All of the top 7 CROs are now able to leverage Veeva Vault CDMS capabilities to modernize clinical data management and build high-quality studies faster.<\/p>\n

The growth of Veeva\u2019s CRO partner program is enabling an industrywide shift to a modern clinical data management platform that better meets the needs of today\u2019s clinical trials. Now 6 out of the top 7 global CROs have access to the support and training needed to build and execute studies with Veeva. As the need to run faster and more efficient trials grows, CROs are using Veeva’s advanced technology to help sponsors improve trial performance.<\/p>\n

\u201cVeeva is enabling CROs to work more effectively with sponsors during the build process to accelerate trial starts,\u201d said Henry Levy, general manager of Veeva Vault CDMS. \u201cOur CRO partners are leading the way towards faster, more collaborative studies and continued excellence in trials.\u201d<\/p>\n

Vault CDMS is a modern cloud application suite that combines electronic data capture (EDC)<\/a>, coding<\/a>, data cleaning<\/a>, and reporting<\/a>. Customers are able to build study databases in six weeks or less and make mid-study amendments with zero downtime, freeing customers to run the trials they want without technology limitations.<\/p>\n

Emerging biotechs are benefitting from the growing number of CROs adopting Vault CDMS. The access to a modern clinical data management solution provides them with the speed and nimbleness to accelerate clinical research. <\/p>\n

The six global CROs joining Veeva\u2019s partner program are Covance, ICON, Parexel, PPD, PRA Health Sciences, and Syneos Health. For CROs interested in learning more about the program, contact pr@veeva.com<\/a>.<\/p>\n

What CROs are saying about Veeva Vault CDMS:<\/strong>
\n\u201cICON supports clients to accelerate clinical development and advance healthcare through applied technology,\u201d said Lalit Pai, senior vice president, biometrics at ICON<\/a>. \u201cVeeva\u2019s innovative clinical data management platform is enabling us to manage and deliver seamless integration for our clients and meet rigorous, global quality standards.\u201d<\/p>\n

\u201cVeeva has an outstanding reputation in the industry and within our organization, as we have widely adopted many of its other platforms,\u201d said Simon Fleming, vice president, data management at Parexel<\/a>. \u201cVeeva Vault CDMS provides us with an exciting opportunity to further build on our relationship and provide customers with more choice and flexibility.\u201d<\/p>\n

\u201cPPD continues to expand our technology offerings focused on providing accelerated decision-making for our customers,\u201d said Rob Petrie, senior vice president and chief technology officer at PPD<\/a>. \u201cThe implementation of Veeva Vault CDMS provides PPD the flexibility to continue to provide innovative technologies, furthering PPD\u2019s mission of bending the time and cost curve of drug development and enabling our clinical research teams to continue to raise the bar by providing the highest level of service and quality to our customers.\u201d<\/p>\n

\u201cVeeva Vault CDMS is a valuable addition to our existing biometrics technology offerings and will provide our clients and partners with a greater choice,\u201d said Michael Goedde, vice president, global data operations at PRA Health Sciences<\/a>. \u201cVeeva has been a respected and valued partner of ours for many years, and now we will be able to further enhance our clinical data management services as the drug development industry evolves.\u201d <\/p>\n

\u201cAt Syneos Health, our focus has always been on running clinical trials in the most efficient and integrated manner, and with the highest quality processes and procedures,\u201d said Paul Colvin, president, clinical solutions at Syneos Health<\/a>. \u201cOur long-standing relationship with Veeva, combined with Veeva Vault CDMS, will allow us to accelerate our operational capabilities and work more collaboratively with our clients.\u201d<\/p>\n

Additional Information<\/strong>
\nFor more on Veeva Vault CDMS, visit: veeva.com\/CDMS<\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veeva_eu on Twitter: twitter.com\/veeva_eu<\/a>
\nLike Veeva on Facebook: facebook.com\/veevasystems<\/a><\/p>\n

About Veeva Systems<\/strong>
\nVeeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world\u2019s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com\/eu<\/a>.<\/p>\n

Veeva Systems Forward-looking Statements<\/strong>
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time. <\/p>\n

###<\/p>\n

Contact:<\/strong><\/p>\n

Veeva Systems
\npr@veeva.com<\/a><\/p>\n

Deivis Mercado
\nVeeva Systems
\n925-226-8821
\ndeivis.mercado@veeva.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Leading CROs join Veeva Vault CDMS partner program to accelerate study builds and launch higher quality clinical trials.<\/p>\n","protected":false},"featured_media":58063,"parent":0,"template":"","class_list":["post-56024","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-clinical-data-management","resource-area-20-vault-platform-area","resource-product-20-dqs","resource-product-20-edc","resource-product-20-vault-platform","resource-type-news-press-release","resource-type-press-release","region-es","region-it"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t